- Home
- CAN vs ZNTL Comparison
CAN vs ZNTL Comparison
Compare CAN & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAN | ZNTL |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.2M | 118.3M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CAN | ZNTL |
|---|---|---|
| Price | $0.93 | $1.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $3.64 | ★ $5.87 |
| AVG Volume (30 Days) | ★ 30.3M | 551.0K |
| Earning Date | 11-18-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $422,228,000.00 | $26,865,000.00 |
| Revenue This Year | $91.42 | N/A |
| Revenue Next Year | $47.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 83.87 | N/A |
| 52 Week Low | $0.53 | $1.01 |
| 52 Week High | $3.27 | $4.00 |
Technical Indicators
Market Signals| Indicator | CAN | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 43.86 | 48.12 |
| Support Level | $0.90 | $1.31 |
| Resistance Level | $1.02 | $1.39 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 39.73 | 61.11 |
Price Performance
Historical ComparisonAbout CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.